- Home
- PAAI vs NRXS Comparison
PAAI vs NRXS Comparison
Compare PAAI & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAAI | NRXS |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 78.9M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PAAI | NRXS |
|---|---|---|
| Price | $1.26 | $7.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 5.0M | 132.0K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 191.93 | 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,892,000.00 | $3,569,282.00 |
| Revenue This Year | N/A | $132.54 |
| Revenue Next Year | $5.00 | $138.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 27.46 | ★ 32.89 |
| 52 Week Low | $0.87 | $2.21 |
| 52 Week High | $3.47 | $9.33 |
Technical Indicators
Market Signals| Indicator | PAAI | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 58.90 |
| Support Level | $0.98 | $6.69 |
| Resistance Level | $1.90 | $7.70 |
| Average True Range (ATR) | 0.51 | 0.55 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 15.76 | 75.64 |
Price Performance
Historical ComparisonAbout PAAI Paradium.AI Inc. Common Stock
Paradium.AI Inc is an AI technology company. The group operates as a centralized, AI-optimized infrastructure that puts the tools, data, and reach media entrepreneurs could never build alone directly into their hands. Its products are Infosentience, Encore, and Cutter Studios.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).